No experience
Employment Type:
Job Category:
Business Development
Development Intern - Downstream Process Development
(This job is no longer available)
Grad Date

Not sure what types of jobs you are interested in?

Explore Jobs
Based on Your Education

Follow This Company

Job Description

Position Summary

The development intern is responsible for performing assigned experimental tasks to support the development and optimization of downstream processes to support Alexion's therapeutic protein candidates. The intern will learn and apply chromatography and filtration principles that will assist the development of innovative continuous and connected downstream processes. The intern will demonstrate the impact of these engineering solutions on productivity and cost of goods. The intern will work in collaboration with other scientific staff in R&D and Global Product Development.

Principal Responsibilities

* Executes experimental studies to develop, optimize, or characterize manufacturing processes for therapeutic protein candidates under supervision (60-70%)
* Document study results in notebooks, forms, and technical reports (10-20%)
* Communicate and present scientific findings in process development and global product development groups (10-20%)


A successful candidate will typically have:

* 0-2 years of experience working in a relevant laboratory setting
* Understanding/coursework in the fundamentals of biology, chemistry, and engineering
* Ability/desire to learn new techniques
* Good interpersonal, collaborative and communication skills
* Experience with various MS Office programs, including Word, Excel, Outlook, and PowerPoint


A successful candidate will typically complete most of core courses, or hold a BS degree in Biology, Biotechnology, Biochemistry, Chemistry, Biomedical Engineering, Chemical Engineering or related discipline from an accredited university.

* LI-DI1

About Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company engaged in the discovery, development and delivery of biologic therapeutic products for the treatment disease, including hematologic and neurologic diseases, cancer and autoimmune disorders. The Company has one marketed product, Soliris (eculizumab), which is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In June 2007, the European Commission (E.C.) approved the use of Soliris for patients with PNH in the European Union, which also serves as the basis for approval in Iceland and Norway. Alexion has focused its product development programs on anti-inflammatory therapeutics for diseases. (Source: 10-K)